Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL509456 |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
ABCC2/Canalicular multispecific organic anion transporter 1 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2073676] [GtoPdb: 780] [UniProtKB: Q63120] | ||||||||
ChEMBL | TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells | F | 5.01 | pIC50 | 9830 | nM | IC50 | Mol Pharmacol (2001) 59: 1077-1085 [PMID:11306690] |
CysLT1 receptor/Cysteinyl leukotriene receptor 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1798] [GtoPdb: 269] [UniProtKB: Q9Y271] | ||||||||
GtoPdb | - | - | 7.8 | pKi | - | - | - | Mol Pharmacol (1998) 53: 750-8 [PMID:9547367] |
GtoPdb | - | - | 6.97 | pIC50 | 107 | nM | IC50 | Nature (1999) 399: 789-93 [PMID:10391245] |
GtoPdb | - | - | 6.41 | pEC50 | 391 | nM | EC50 | Mol Pharmacol (2011) 79: 270-8 [PMID:21078884] |
GtoPdb | - | - | 6.67 | pEC50 | 212 | nM | EC50 | Nature (1999) 399: 789-93 [PMID:10391245] |
ChEMBL | Agonist activity at human CysLT1 receptor | F | 6.98 | pEC50 | 104 | nM | EC50 | J Med Chem (2021) 64: 16512-16529 [PMID:34767347] |
GtoPdb | - | - | 7.24 | pEC50 | 58 | nM | EC50 |
Mol Pharmacol (1999) 56: 657-63 [PMID:10462554]; Biochem Biophys Res Commun (2000) 274: 316-22 [PMID:10913337]; Mol Pharmacol (2000) 58: 1601-8 [PMID:11093801] |
CysLT2 receptor/Cysteinyl leukotriene receptor 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4330] [GtoPdb: 270] [UniProtKB: Q9NS75] | ||||||||
GtoPdb | - | - | 6.5 | pKi | - | - | - | Mol Pharmacol (1998) 53: 750-8 [PMID:9547367] |
GtoPdb | - | - | 5.72 | pIC50 | 1890 | nM | IC50 | Biochem Biophys Res Commun (2000) 274: 316-22 [PMID:10913337] |
GtoPdb | - | - | 6.16 | pIC50 | 693 | nM | IC50 |
J Biol Chem (2000) 275: 30531-6 [PMID:10851239]; Mol Pharmacol (2000) 58: 1601-8 [PMID:11093801] |
GtoPdb | - | - | 5.92 | pEC50 | 1208 | nM | EC50 |
J Biol Chem (2000) 275: 30531-6 [PMID:10851239]; Mol Pharmacol (2011) 79: 270-8 [PMID:21078884] |
ChEMBL | Agonist activity at human CysLT2 receptor | F | 6.53 | pEC50 | 293 | nM | EC50 | J Med Chem (2021) 64: 16512-16529 [PMID:34767347] |
GtoPdb | - | - | 7.11 | pEC50 | 77 | nM | EC50 |
Biochem Biophys Res Commun (2000) 274: 316-22 [PMID:10913337]; Mol Pharmacol (2000) 58: 1601-8 [PMID:11093801] |
P2Y12 receptor/Purinergic receptor P2Y12 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2001] [GtoPdb: 328] [UniProtKB: Q9H244] | ||||||||
ChEMBL | Agonist activity at human P2Y12 receptor | F | 8.89 | pEC50 | 1.3 | nM | EC50 | J Med Chem (2009) 52: 5803-5815 [PMID:19739647] |
GPR17 in Mouse [GtoPdb: 88] [UniProtKB: Q6NS65] | ||||||||
GtoPdb | - | - | 9.51 | pEC50 | 0.31 | nM | EC50 | PLoS ONE (2008) 3: e3579 [PMID:18974869] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]